Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma: early-phase trial registry
1 of 2 indexed Recurrent Fallopian Tube High Grade Serous Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma: 2 US clinical trials tracked, 1 recruiting.
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 1 of these trials.
Enrollment posture brief
Registry condition recurrent-fallopian-tube-high-grade-serous-adenocarcinoma
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Fallopian Tube High Grade Serous Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Mayo Clinic
NCT05920798
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
NCT04739800
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Fallopian Tube High Grade Serous Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Fallopian Tube High Grade Serous Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Fallopian Tube High Grade Serous Adenocarcinoma page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Fallopian Tube High Grade Serous Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Recurrent Fallopian Tube High Grade Serous Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Fallopian Tube High Grade Serous Adenocarcinoma condition card totals 2 registered trials; most-linked intervention Computed Tomography; top US site state Arizona. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.